<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-sa">

			<div class="slide-title red">
				Self-assessment
			</div>


			<div class="content-container">
				<!-- <div class="inhibitNavigationSwipe disable-sa"></div> -->
			
				<div class="swipe inhibitNavigationSwipe" id="glossary-slider">
				    <div class="swipe-wipe">

				        <div>

				        	<div class="question">
				        		<h2>Question 1</h2>

					        	<p>TPO-R can be found on the surface of:</p>

					        	<div class="answers" data-question="one">
					        		<button class="answer">A. Megakaryocyte precursor cells and megakaryocytes</button>

						        	<button class="answer">B. Mature platelets only</button>

						        	<button class="answer">C. Erythroid progenitor cells</button>

						        	<button class="answer correct">D. Early bone marrow progenitor cells of all lineages</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="one">SUBMIT</button> -->
				        	
				        </div>


				        <div>
				        	
							<div class="question">
				        		<h2>Question 2</h2>

					        	<p>Which of the following is a traditional first-line treatment for ITP?</p>

					        	<div class="answers" data-question="two">
					        		<button class="answer correct">A. Anti-D immunoglobulins</button>

						        	<button class="answer">B. Stem cell transplant</button>

						        	<button class="answer">C. Horse ATG globulin with ciclosporin</button>

						        	<button class="answer">D. High-dose cyclophosphamide</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="two">SUBMIT</button> -->

				        </div>

				        
				         <div>
				        	
							<div class="question">
				        		<h2>Question 3</h2>

					        	<p>Eltrombopag acts by:</p>

					        	<div class="answers" data-question="three">
					        		<button class="answer">A. Inhibiting autoimmune destruction of platelets, although the mechanism is unclear</button>

						        	<button class="answer correct">B. Binding to TPO-Rs to initiate signalling cascades that induce proliferation and differentiation of bone marrow progenitor cells</button>

						        	<button class="answer">C. Stimulating TPO production from the bone marrow stroma</button>

						        	<button class="answer">D. Reducing platelet consumption</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="three">SUBMIT</button> -->

				        </div>

				        <div>
				        	
							<div class="question">
				        		<h2>Question 4</h2>

					        	<p>TPO-R knockout mice exhibit:</p>

					        	<div class="answers" data-question="four">
					        		<button class="answer">A. Increased HSCs and HPCs</button>

						        	<button class="answer">B. Compensatory mechanisms to maintain haematopoiesis</button>

						        	<button class="answer correct">C. Reduced numbers of HSCs and HPCs</button>

						        	<button class="answer">D. Reduced platelet counts only</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="four">SUBMIT</button> -->

				        </div>

				        <div>
				        	
							<div class="question">
				        		<h2>Question 5</h2>

					        	<p style="margin:0 0 10px">What is notable about TPO in the context of ITP and aplastic anaemia?</p>

					        	<div class="answers" data-question="five">
					        		<button class="answer correct">A. TPO levels are within the normal range or are moderately increased in ITP, but high in aplastic anaemia</button>

						        	<button class="answer">B. TPO levels are high in ITP, but low in aplastic anaemia</button>

						        	<button class="answer">C. TPO activity is altered because of different genetic mutations in ITP and aplastic anaemia</button>

						        	<button class="answer">D. TPO levels are low in both conditions</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="five">SUBMIT</button> -->

				        </div>

				        <div>
				        	
							<div class="question">
				        		<h2>Question 6</h2>

					        	<p>Which <i>in vivo</i> observations support the use of eltrombopag to treat bone marrow failure?</p>

					        	<div class="answers" data-question="six">
					        		<button class="answer">A. Increased circulating levels of platelets</button>

						        	<button class="answer">B. Multilineage haematopoiesis and increased circulating levels of platelets and WBCs</button>

						        	<button class="answer">C. Multilineage haematopoiesis and increased circulating levels of platelets and WBCs, although there was no effect on HSC expansion</button>

						        	<button class="answer correct">D. Accelerated HSC/HPC expansion, multilineage haematopoiesis and increased circulating levels of platelets and WBCs</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="six">SUBMIT</button> -->

				        </div>

				        <div>
				        	
							<div class="question">
				        		<h2>Question 7</h2>

					        	<p>The anticipated indication for eltrombopag is as a treatment for:</p>

					        	<div class="answers" data-question="seven">
					        		<button class="answer">A. Moderate aplastic anaemia</button>

						        	<button class="answer">B. Thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy</button>

						        	<button class="answer correct">C. Cytopenias in patients with SAA who have had an insufficient response to IST</button>

						        	<button class="answer">D. Thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="seven">SUBMIT</button> -->

				        </div>

				        <div>
				        	
							<div class="question">
				        		<h2 style="margin-bottom:10px">Question 8</h2>

					        	<p style="margin: 8px 0;">In the phase II study of eltrombopag for refractory aplastic anaemia, what percentage of patients with severe aplastic anaemia met the primary response criteria in ≥1 cell lineage?</p>

					        	<div class="answers" data-question="eight">
					        		<button class="answer">A. 59%</button>

						        	<button class="answer correct">B. 40%</button>

						        	<button class="answer">C. 64%</button>

						        	<button class="answer">D. 81%</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="eight">SUBMIT</button> -->

				        </div>

				        <div>
				        	
							<div class="question">
				        		<h2>Question 9</h2>

					        	<p>In the phase II study of eltrombopag for refractory aplastic anaemia, how many patients no longer required platelet transfusions at Week 12?</p>

					        	<div class="answers" data-question="nine">
					        		<button class="answer">A. 11/25</button>

						        	<button class="answer">B. 7/11</button>

						        	<button class="answer correct">C. 9/11</button>

						        	<button class="answer">D. 9/25</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="nine">SUBMIT</button> -->

				        </div>

				        <div>
				        	
							<div class="question">
				        		<h2>Question 10</h2>

					        	<p>In the phase II study of eltrombopag for refractory aplastic anaemia, which cell types had improved levels in patients who achieved a multilineage response?</p>

					        	<div class="answers" data-question="ten">
					        		<button class="answer">A. Platelets, natural killer cells and neutrophils</button>

						        	<button class="answer">B. Platelets, RBCs and macrophages</button>

						        	<button class="answer">C. Platelets, RBCs and granulocytes</button>

						        	<button class="answer correct">D. Platelets, RBCs and neutrophils</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="ten">SUBMIT</button> -->

				        </div>


				         <div>
				        	
							<div class="question">
				        		<h2>Question 11</h2>

					        	<p>According to which parameter is the dosage of eltrombopag adjusted?</p>

					        	<div class="answers" data-question="eleven">
					        		<button class="answer correct">A. Platelet count</button>

						        	<button class="answer">B. Absolute neutrophil count</button>

						        	<button class="answer">C. Reticulocyte count</button>

						        	<button class="answer">D. Haemoglobin level</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="eleven">SUBMIT</button> -->

				        </div>


				         <div>
				        	
							<div class="question">
				        		<h2>Question 12</h2>

					        	<p>What is the maximum dose of eltrombopag for severe aplastic anaemia?</p>

					        	<div class="answers" data-question="twelve">
					        		<button class="answer">A. 25 mg</button>

						        	<button class="answer">B. 50 mg</button>

						        	<button class="answer correct">C. 150 mg</button>

						        	<button class="answer">D. 75 mg</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="twelve">SUBMIT</button> -->

				        </div>


				         <div>
				        	
							<div class="question">
				        		<h2>Question 13</h2>

					        	<p>After how many weeks should eltrombopag be discontinued in the event of non-response?</p>

					        	<div class="answers" data-question="thirteen">
					        		<button class="answer">A. 8</button>

						        	<button class="answer">B. 12</button>

						        	<button class="answer correct">C. 16</button>

						        	<button class="answer">D. 4</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="thirteen">SUBMIT</button>
 -->
				        </div>


				         <div>
				        	
							<div class="question">
				        		<h2>Question 14</h2>

					        	<p>Which of the following is not a common adverse effect associated with eltrombopag treatment?</p>

					        	<div class="answers" data-question="fourteen">
					        		<button class="answer">A. Nausea</button>

						        	<button class="answer">B. Fatigue</button>

						        	<button class="answer">C. Headache</button>

						        	<button class="answer correct">D. Abdominal infection</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="fourteen">SUBMIT</button>
 -->
				        </div>


				         <div>
				        	
							<div class="question">
				        		<h2>Question 15</h2>

					        	<p>What percentage of patients with SAA have reported cytogenetic abnormalities?</p>

					        	<div class="answers" data-question="fifteen">
					        		<button class="answer">3–5%</button>

						        	<button class="answer">B. 5–10%</button>

						        	<button class="answer correct">C. 15–20%</button>

						        	<button class="answer">D. 20–25%</button>
					        	</div>

				        	</div>

				        	<!-- <button class="submit blue-button" data-question="fifteen">SUBMIT</button> -->

				        </div>


				         <div class="summary-section-1">
				        	
							<div class="summary-section">
				        		<h2>Summary</h2>

				        		<button class="submit blue-button show-results">SHOW RESULTS</button>

					        	<button class="submit blue-button navigate" data-navtarget="slide_sa_3">RETAKE ASSESSMENT</button>

					        	<button class="submit blue-button navigate" data-navtarget="mod_3_home">RESTART MODULE</button>

					        	<div class="mod-results">
					        		<p>you scored <span></span> out of 25</p>

						        	<!-- <ul>
						        		
						        	</ul>
						        	<ul>
						        		
						        	</ul> -->

						        	<div class="results-table">
						        		
										<table>
											
										</table>

						        	</div>
					        	</div>

				        	</div>

				        
				        </div>

				    </div>
				</div>

				<button class="swipe-next" style="float:right;"></button>
				<button class="swipe-prev"></button>

			</div>

		</div>

	</div>
</div>
<script>
	addInviewFunction(function () { 

        $('.question button').on('click tap',function(){

        	$(this).parent().children().removeClass('active');

        	$(this).addClass('active')

        	var questionNo = $(this).parent().attr('data-question');

        	var correct = $(this).hasClass('correct');

        	// for question no : correct or incorrect inside ul

        	// if(correct){
        	// 	questions[questionNo] = 'Correct';
        	// }else{
        	// 	questions[questionNo] = 'Incorrect';	
        	// }

        	//for question correct or incorrect inside table

        	if(correct){
        		questions[questionNo] = {};
        		questions[questionNo].status = 'Correct';
        		questions[questionNo].question = $(this).parent().prev().html();

        	}else{
        		questions[questionNo] = {};
        		questions[questionNo].status = 'Inorrect';
        		questions[questionNo].question = $(this).parent().prev().html();	
        	}
  
        });



        window.questions = {};

        var score = '0';

		
		$('.summary-section-1 .show-results').on('click tap',function(){
			console.log('show results');

		// for question no : correct or incorrect inside ul
			// if($('.summary-section ul li').length=== 0){

			// 	var count = 0;
			// 	for(key in questions){
		 //        	var val = questions[key];
		 //        	count++;
		 //        	// $('.summary-section ul').append('<li>Question '+key+': '+val+'</li>');

		 //        	if(count < 10){
		 //        		if (val === 'Correct') {
			//         		score++;
			//         		$('.summary-section ul:eq(0)').append('<li>Question '+key+': <span class="correct">'+val+'</span></li>');
			//         	}else{
			//         		$('.summary-section ul:eq(0)').append('<li>Question '+key+': <span class="incorrect">'+val+'</span></li>');
			//         	};
		 //        	}else{
		 //        		if (val === 'Correct') {
			//         		score++;
			//         		$('.summary-section ul:eq(1)').append('<li>Question '+key+': <span class="correct">'+val+'</span></li>');
			//         	}else{
			//         		$('.summary-section ul:eq(1)').append('<li>Question '+key+': <span class="incorrect">'+val+'</span></li>');
			//         	};
		 //        	}

		        	

		 //        }

		 //        $('.summary-section p span').html(score);

		 //        $('.mod-results').fadeIn(); 

		 //        $('.question .answers button').attr('disabled','true'); 

			// }

			if($('.summary-section table tr').length===0){

				for (key in questions){

					var obj = questions[key];

					if(obj.status === 'Correct'){
						score++;
						$('.summary-section table').append("<tr><td>"+obj.question+"</td><td class='correct'>Correct</td></tr>");
					}else{
						$('.summary-section table').append("<tr><td>"+obj.question+"</td><td class='incorrect'>Incorrect</td></tr>");
					}

				}


				$('.summary-section p span').html(score);

		        $('.mod-results').fadeIn(); 

		        $('.question .answers button').attr('disabled','true'); 

			}
			

		});



        

        
    });
</script>